ABIONYX Pharma SA (ABNX) Stock Statistics & Valuation Metrics

ABIONYX Pharma SA has a market cap or net worth of €130.17M. The enterprise value is €130.56M.

ABIONYX Pharma SA has 35,511,654 shares outstanding. The number of shares has decreased by -2.65% in one year.

ABIONYX Pharma SA’s return on equity (ROE) is -1.30 and return on invested capital (ROIC) is -65.53%.

The current PE Ratio of ABIONYX Pharma SA is ―. ABIONYX Pharma SA’s PEG ratio is -1.05.

In the last 12 months, ABIONYX Pharma SA had revenue of 4.06M and earned -5.55M in profits. Earnings per share was -0.15.

In the last 12 months, operating cash flow was -2.94M and capital expenditures -242.00K, giving a free cash flow of -3.02M billion.

ABIONYX Pharma SA pays an annual dividend of ―, resulting in a dividend yield of ―

ABIONYX Pharma SA upcoming earnings date is Sep 24, 2026, During Market Hours (Confirmed).

ABIONYX Pharma SA as a current ratio of 1.06, with Debt / Equity ratio of 89.30%

In the past 12 months, ABIONYX Pharma SA has paid -688.00K in taxes.

ABIONYX Pharma SA EV to EBITDA ratio is -23.64, with an EV/FCF ratio of -42.47.

ABIONYX Pharma SA has €3.52M in cash and marketable securities with €3.81M in debt, giving a net cash position of -€284.00K billion.

Gross margin is 10.26%, with operating margin of -153.95%, and net profit margin of -136.60%.

The average price target for ABIONYX Pharma SA is ―, which is 11.43% higher than the current price. The consensus rating is ―